Patents by Inventor Timothy J. Cardozo

Timothy J. Cardozo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Propeptide fusion comprising a mutated clostridium botulinum neurotoxin and a VHH domain
    Patent number: 11897921
    Abstract: The present invention is directed to a fusion protein comprising a light chain region of a Clostridial neurotoxin and a heavy chain region of a Clostridial neurotoxin, where the light and heavy chain regions are linked by a disulfide bond. The fusion protein also has a single chain antibody positioned upstream of the light chain region, where the single chain antibody possesses antigen-binding activity. Also disclosed are therapeutic agents, treatment methods, propeptide fusions, isolated nucleic acid molecules, expression systems, host cells, and methods of expressing fusion proteins.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: February 13, 2024
    Assignee: NEW YORK UNIVERSITY
    Inventors: Konstantin Ichtchenko, Edwin Vazquez-Cintron, Philip A. Band, Timothy J. Cardozo
  • Inhibitors of CaMKK2 and uses of same
    Patent number: 11396505
    Abstract: The present disclosure provides compounds suitable for inhibiting CaMKK2. Also provided are compositions and methods of treating diseases associated with CaMKK2.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: July 26, 2022
    Assignee: New York University
    Inventors: Dan Sherman, Timothy J. Cardozo
  • INHIBITORS OF CAMKK2 AND USES OF SAME
    Publication number: 20200369656
    Abstract: The present disclosure provides compounds suitable for inhibiting CaMKK2. Also provided are compositions and methods of treating diseases associated with CaMKK2.
    Type: Application
    Filed: May 26, 2020
    Publication date: November 26, 2020
    Inventors: Dan Sherman, Timothy J. Cardozo
  • Small molecule malarial Aldolase-TRAP enhancers and glideosome inhibitors
    Patent number: 9873661
    Abstract: In one aspect, the present invention relates to a method of identifying compounds useful in modifying the activity of Aldolase.
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: January 23, 2018
    Assignees: New York University, The Johns Hopkins University
    Inventors: Timothy J. Cardozo, Jürgen Bosch, Sondra Maureen Nemetski
  • CLOSTRIDIAL NEUROTOXIN FUSION PROTEINS, PROPEPTIDE FUSIONS, THEIR EXPRESSION, AND USE
    Publication number: 20160159866
    Abstract: The present invention is directed to a fusion protein comprising a light chain region of a Clostridial neurotoxin and a heavy chain region of a Clostridial neurotoxin, where the light and heavy chain regions are linked by a disulfide bond. The fusion protein also has a single chain antibody positioned upstream of the light chain region, where the single chain antibody possesses antigen-binding activity. Also disclosed are therapeutic agents, treatment methods, propeptide fusions, isolated nucleic acid molecules, expression systems, host cells, and methods of expressing fusion proteins.
    Type: Application
    Filed: December 9, 2015
    Publication date: June 9, 2016
    Applicant: New York University
    Inventors: Konstantin Ichtchenko, Edwin Vazquez-Cintron, Philip A. Band, Timothy J. Cardozo
  • Pharmaceutical compositions and treatment of genetic diseases associated with nonsense mediated RNA decay
    Patent number: 9216180
    Abstract: The present invention relates to pharmaceutical compositions comprising a compound and a pharmaceutically acceptable carrier. The present invention is also directed to a method of treating a genetic disease caused by premature termination codons, or other conditions that render messenger ribonucleic acid (mRNA) susceptible to nonsense mediated RNA decay, in a subject. Also disclosed is a method of inhibiting nonsense mediated RNA decay and/or induction of autophagy. The present invention also relates to a method of identifying inhibitors of nonsense mediated RNA decay and/or inducing autophagy. The present invention further relates to a method of inhibiting nonsense mediated RNA decay and/or induction of autophagy in a subject.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: December 22, 2015
    Assignee: New York University
    Inventors: Lawrence B. Gardner, Timothy J. Cardozo, Leenus Martin
  • METHOD OF IDENTIFYING THE MOLECULAR BASIS OF THE ACTIVITY OF A DRUG COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND TREATMENT METHODS
    Publication number: 20150134266
    Abstract: The present invention relates to a method of identifying the molecular basis of a drug compound's activity. The invention further relates to a pharmaceutical composition, a kit for treating psychosis in a subject, and a method for treating psychosis and/or schizophrenia.
    Type: Application
    Filed: November 12, 2014
    Publication date: May 14, 2015
    Applicant: NEW YORK UNIVERSITY
    Inventors: Timothy J. CARDOZO, Evgeny V. SHMELKOV
  • Immunogen comprising the HIV GP120 V3 loop in a conformation that induces broadly neutralizing antibodies
    Patent number: 8961987
    Abstract: Insertion of HIV-1 V3 loop peptides from the viral glycoprotein gp120 into selected, immunogenic scaffold proteins results in a recombinant polypeptide that is a potent V3 immunogen. V3 immunogens include natural and consensus V3 sequences and cyclic and reverse peptides. Preferred scaffold proteins are Cholera Toxin subunit B and homologues thereof including closely related E. coli enterotoxins. Such immunogenic polypeptides induce broadly reactive anti-gp120 antibodies specific for V3 epitopes that can neutralize heterologous HIV-1 subtypes and strains. These polypeptide, methods for preparing them, and methods for inducing anti-gp120 (V3-specific) antibody) responses using them are disclosed.
    Type: Grant
    Filed: August 20, 2008
    Date of Patent: February 24, 2015
    Assignees: New York University, Molsoft LLC, University of Massachusetts
    Inventors: Susan Zolla-Pazner, Miroslaw K. Gorny, Timothy J. Cardozo, Xiang-peng Kong, Ruben Abagyan, Maxim Totrov, Shan Lu, Abraham Pinter
  • SMALL MOLECULE MALARIAL ALDOLASE-TRAP ENHANCERS AND GLIDEOSOME INHIBITORS
    Publication number: 20140275088
    Abstract: In one aspect, the present invention relates to a method of identifying compounds useful in modifying the activity of Aldolase.
    Type: Application
    Filed: October 25, 2012
    Publication date: September 18, 2014
    Inventors: Timothy J. Cardozo, Jürgen Bosch, Sondra Maureen Nemetski
  • PHARMACEUTICAL COMPOSITIONS AND TREATMENT OF GENETIC DISEASES ASSOCIATED WITH NONSENSE MEDIATED RNA DECAY
    Publication number: 20140094457
    Abstract: The present invention relates to pharmaceutical compositions comprising a compound and a pharmaceutically acceptable carrier. The present invention is also directed to a method of treating a genetic disease caused by premature termination codons, or other conditions that render messenger ribonucleic acid (mRNA) susceptible to nonsense mediated RNA decay, in a subject. Also disclosed is a method of inhibiting nonsense mediated RNA decay and/or induction of autophagy. The present invention also relates to a method of identifying inhibitors of nonsense mediated RNA decay and/or inducing autophagy. The present invention further relates to a method of inhibiting nonsense mediated RNA decay and/or induction of autophagy in a subject.
    Type: Application
    Filed: October 2, 2013
    Publication date: April 3, 2014
    Applicant: NEW YORK UNIVERSITY
    Inventors: Lawrence B. Gardner, Timothy J. Cardozo, Leenus Martin
  • IMMUNOGEN PRESENTING HIV GP120 V3 LOOP IN A CONFORMATION THAT INDUCES BROADLY NEUTRALIZING ANTIBODIES
    Publication number: 20090098144
    Abstract: Insertion of HIV-1 V3 loop peptides from the viral glycoprotein gp120 into selected, immunogenic scaffold proteins results in a recombinant polypeptide that is a potent V3 immunogen. V3 immunogens include natural and consensus V3 sequences and cyclic and reverse peptides. Preferred scaffold proteins are Cholera Toxin subunit B and homologues thereof including closely related E. coli enterotoxins. Such immunogenic polypeptides induce broadly reactive anti-gp120 antibodies specific for V3 epitopes that can neutralize heterologous HIV-1 subtypes and strains. These polypeptide, methods for preparing them, and methods for inducing anti-gp120 (V3-specific) antibody) responses using them are disclosed.
    Type: Application
    Filed: August 20, 2008
    Publication date: April 16, 2009
    Applicants: New York University, Molsoft LLC, University of Massachusetts, University of Medicine and Dentistry of New Jersey
    Inventors: Susan ZOLLA-PAZNER, Miroslaw K. Gorny, Timothy J. Cardozo, Xiang-peng Kong, Ruben Abagyan, Maxim Totrov, Shan Lu, Abraham Pinter
  • Method of orally treating inflammatory skin conditions with prodrugs of 5-fluorouracil
    Patent number: 7026301
    Abstract: The present invention relates to the treatment of inflammatory skin conditions, including psoriasis, with a prodrug of 5-fluorouracil. The invention relates to methods for treatment of psoriasis with capecitabine, an oral prodrug of 5-fluorouracil.
    Type: Grant
    Filed: October 17, 2003
    Date of Patent: April 11, 2006
    Assignee: New York University
    Inventors: Timothy J. Cardozo, John C. Pui